Mike Ross joined SV Health Investors in 2001, became Managing Partner in 2002, and leads biotech investments in the US and UK. He previously worked at Genentech and founded Arris Pharmaceutical.








At firms with a similar stage, sector and check size.





One email when Mike's firm raises a fund, adds a partner or shows new activity.

Raising a pre-seed or seed round? We write $1M to $5M first checks and help founders with distribution. A partner reads every deck.
Send your deckMike Ross joined SV Health Investors in 2001, became Managing Partner in 2002, and leads biotech investments in the US and UK. He previously worked at Genentech and founded Arris Pharmaceutical.
SV Health Investors has not reported a check size. It invests at pre-seed, seed, series a, series b.
A warm intro from a founder SV Health Investors backed works best.
tenth employee, team leader, Vice President of Development, Vice President of Medicinal and Biomolecular Chemistry at Genentech; Founding CEO at Arris Pharmaceutical; Vice President of Development at Genentech; Vice President of Medicinal and Biomolecular Chemistry at Genentech.
Last updated 2026-10-15. Is this you? Ask for a correction.